Detail page

Knowledge Web

Person

Carsten Müller-Tidow

Hämatologe

Name	Carsten Müller-Tidow
Time	2017- (Wirkungsdaten)
Place	Heidelberg (Wirkungsort) Deutschland
Gender	männlich
Academic degree	Prof. Dr. med.
Profession	Hämatologe (characteristic profession) Arzt
Variant	Carsten Müller- Tidow Carsten Mueller-Tidow Carsten Muller-Tidow
Related	Universitätsklinikum Heidelberg. Zentrum für Innere Medizin (02/2017-)
Further information	Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie, Ärztlicher Direktor der Medizinischen Klinik V des Universitätsklinikums Heidelberg
Source	https://www.klinikum.uni-heidelberg.de/personen/prof-dr-med-carsten-mueller-tidow-3006 (Stand: 30.05.2024)
Record type	Person
GND-Identifier	1015101798
Record ID	1015101798
Involved in show all CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts Prognostic impact of CEBPA mutational subgroups in adult AML DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-cell lymphomas Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia Proteogenomics refines the molecular classification of chronic lymphocytic leukemia Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study Identification of RPS6KA1 as a mediator of resistance to Venetoclax/Azacytidine-combination treatment in Acute Myeloid Leukemia by genome-scale CRISPR/Cas9 knockout screening Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD S282: A randomized controlled clinical trial demonstrates that plasma from convalescent and vaccinated donors improves outcome of COVID-19 in patients with hematological disease, cancer or immunosuppression The landscape of small nucleolar RNA expression and potential roles of RNA modifications in multiple myeloma Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation Cryostorage to What End? – Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients Funktionelle Bedeutung von snoRNAs bei der Akuten Myeloischen Leukämie Genomic investigation and successful containment of an intermittent common source outbreak of OXA-48-producing enterobacter cloacae related to hospital shower drains Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Carsten Müller-Tidow

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities

DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts

Prognostic impact of CEBPA mutational subgroups in adult AML

DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis

Human and mouse neutrophils share core transcriptional programs in both homeostatic and inflamed contexts

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

The landscape of small nucleolar RNA expression in multiple myeloma is determined by cytogenetic alterations

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level

Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Divergent effects of EZH1 and EZH2 protein expression on the prognosis of patients with T-cell lymphomas

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

Identification of RPS6KA1 as a mediator of resistance to Venetoclax/Azacytidine-combination treatment in Acute Myeloid Leukemia by genome-scale CRISPR/Cas9 knockout screening

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD

S282: A randomized controlled clinical trial demonstrates that plasma from convalescent and vaccinated donors improves outcome of COVID-19 in patients with hematological disease, cancer or immunosuppression

The landscape of small nucleolar RNA expression and potential roles of RNA modifications in multiple myeloma

Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation

Cryostorage to What End? – Autologous Stem Cell Products in Burkitt Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Myeloproliferative Neoplasm Patients

Funktionelle Bedeutung von snoRNAs bei der Akuten Myeloischen Leukämie

Genomic investigation and successful containment of an intermittent common source outbreak of OXA-48-producing enterobacter cloacae related to hospital shower drains

Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response

Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas